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hsCRP GP30 GP36 GP38 
Functional 
effect 
c.1129delC L377fs 27 26.79 yes SU 65 (8.1) 0.21 0.55 1.50 0.22 Damaging 
c.871C>A P291T 15 32.51 yes INS + MET 80 (9.5) 1.60 1.28 2.97 0.42 VUS 
c.1-326del del exon 1 20 34.29 no INS 87 (10.1) 5.42 0.38 1.08 0.23 Damaging 
c.142G>A E48K 42 39.82 yes INS + MET 107 (11.9) 2.00 0.95 2.23 0.47 Benign 
c.872delC P291fs 30 32.15 yes INS 61 (7.7) 0.11 0.16 0.88 0.14 Damaging 
c.139G>C G47R 37 28.80 yes INS + MET + SU 60 (7.6) 1.25 n/a n/a n/a Benign 
c.1816G>A G606S 32 24.00 yes INS 75 (9) 3.98 n/a n/a n/a Benign 
c.872delC P291fs 18 25.73 yes INS 39 (5.7) 0.02 0.58 1.42 0.17 Damaging 
c.1136_1137delCT P379fs 35 23.53 yes MET + SU 45 (6.3) 0.06 0.27 0.97 0.16 Damaging 
c.872dupC G292fs 12 25.18 yes INS 100 (11.3) 0.70 0.96 2.12 0.33 Damaging 
c.872dupC G292fs 17 20.97 no Diet 44 (6.2) 0.10 0.44 1.22 0.17 Damaging 
c.1015G>A G339S 26 29.68 yes INS 67 (8.3) 0.84 0.43 1.00 0.22 Benign 
c.-4A>G c.-4A>G 37 28.56 no MET + SU 83 (9.7) 2.73 0.51 1.02 0.19 Benign 
c.586A>G T196A 42 38.89 yes INS + TZD + MET 87 (10.1) 0.83 1.79 3.67 0.46 Benign 
c.779C>T T260M 25 30.51 yes MET + SU 62 (7.8) 0.01 0.34 0.86 0.16 Damaging 
  
c.404delA D135fs 28 19.29 yes SU 50 (6.7) 0.01 0.52 1.24 0.14 Damaging 
c.1136C>A P379H 44 30.81 yes Diet 56 (7.3) 1.57 0.70 2.01 0.25 Damaging 
c.1047C>A H349Q 33 n/a yes INS 79 (9.4) 1.01 2.03 3.84 0.42 Benign 
c.1165T>G L389V 37 32.30 no INS + MET + SU 77 (9.2) 12.07 0.62 1.37 0.25 Benign 
c.666G>T K222N 18 32.01 yes SU 57 (7.4) 0.20 0.33 0.97 0.16 Damaging 
c.451G>A G151S 35 26.37 yes MET + SU 45 (6.3) 0.80 0.72 1.62 0.25 Damaging 
c.1136C>G P379R 28 19.94 yes INS + MET 60 (7.6) 0.60 0.29 1.10 0.17 Damaging 
c.1544C>T T515M 33 27.99 yes INS 53 (7.0) 4.60 1.11 2.31 0.32 VUS 
c.862G>T G288W 39 38.40 no Diet 37 (5.5) 15.70 1.24 3.31 0.49 Benign 
c.751G>A A251T 39 27.14 no Diet 51 (6.8) 0.30 0.64 1.59 0.23 VUS 
c.685C>T R229* 25 19.05 yes Glinide 56 (7.3) 0.40 0.35 1.12 0.11 Damaging 
c.872dupC G292fs 23 23.95 n/a INS 57 (7.4) 0.40 0.52 1.23 0.18 Damaging 
c.1136_1137delCT P379fs 16 22.28 n/a Diet 48 (6.5) 0.10 0.42 1.07 0.12 Damaging 
c.8C>G S3C 37 24.17 yes INS+ glinide 107 (11.9) 1.40 0.73 1.60 0.26 VUS 
INS – insulin; MET – metformin; SU – sulphonylurea derivative; TZD – thiazolidinedione derivative 
 
  
Supplemental Table S2 Comparison of plasma protein N-glycome and hsCRP 
between subjects with likely damaging HNF1A alleles and subjects without rare 
HNF1A alleles, with young adult-onset non-autoimmune diabetes, using general 
linear model and case control meta-analysis on both, UK and Croatian cohorts. 
Statistically significant p-values are marked in bold.  
 UK cohort Croatian cohort Meta-analysis 
marker effect SE p-value effect SE p-value effect SE p-value adjusted p-value*  
GP30 -1.31 0.30 1.23E-05 -1.12 0.44 9.79E-03 -1.25 0.25 4.25E-07 1.00E-05 
hsCRP -1.25 0.30 3.90E-05 -1.09 0.45 1.15E-02 -1.20 0.25 1.97E-06 3.09E-05 
GP38 -1.12 0.31 2.54E-04 -1.17 0.45 8.38E-03 -1.14 0.25 7.10E-06 7.98E-05 
GP36 -1.14 0.30 1.78E-04 -0.98 0.44 2.34E-02 -1.09 0.25 1.34E-05 1.05E-04 
GP25 -1.05 0.31 5.65E-04 -0.54 0.46 2.36E-01 -0.90 0.26 4.50E-04 2.35E-03 
GP42 -0.88 0.31 4.17E-03 -0.80 0.45 7.32E-02 -0.86 0.26 7.98E-04 3.75E-03 
GP27.28 0.65 0.30 3.18E-02 0.85 0.44 5.29E-02 0.71 0.25 4.49E-03 1.46E-02 
GP33 0.70 0.30 1.70E-02 0.70 0.45 1.16E-01 0.70 0.25 4.59E-03 1.46E-02 
GP40 0.71 0.31 1.99E-02 0.74 0.45 9.92E-02 0.72 0.25 4.66E-03 1.46E-02 
GP31 0.53 0.30 7.87E-02 0.66 0.45 1.34E-01 0.57 0.25 2.29E-02 6.32E-02 
GP5 0.84 0.31 6.59E-03 -0.18 0.47 6.96E-01 0.53 0.26 4.06E-02 1.06E-01 
GP22 -0.38 0.31 2.15E-01 -0.78 0.46 8.75E-02 -0.50 0.26 4.97E-02 1.23E-01 
GP4 0.52 0.31 8.98E-02 0.36 0.47 4.31E-01 0.47 0.26 6.67E-02 1.57E-01 
GP14 0.85 0.31 6.35E-03 -0.48 0.47 3.03E-01 0.44 0.26 8.82E-02 1.97E-01 
GP10.11 0.17 0.29 5.49E-01 0.85 0.42 4.28E-02 0.39 0.24 1.03E-01 2.21E-01 
GP20.21 0.25 0.31 4.13E-01 0.55 0.46 2.31E-01 0.34 0.26 1.82E-01 3.72E-01 
GP19 0.29 0.32 3.51E-01 0.45 0.46 3.28E-01 0.34 0.26 1.91E-01 3.73E-01 
GP12 0.25 0.32 4.23E-01 0.46 0.45 3.05E-01 0.32 0.26 2.18E-01 4.10E-01 
GP24 -0.34 0.31 2.76E-01 -0.23 0.46 6.16E-01 -0.30 0.26 2.41E-01 4.27E-01 
GP29 0.35 0.29 2.36E-01 0.15 0.44 7.36E-01 0.29 0.25 2.45E-01 4.27E-01 
GP15 -0.29 0.31 3.44E-01 -0.27 0.47 5.57E-01 -0.29 0.26 2.70E-01 4.49E-01 
GP6 0.37 0.31 2.26E-01 0.07 0.47 8.78E-01 0.28 0.26 2.77E-01 4.49E-01 
GP41 0.28 0.31 3.55E-01 0.17 0.46 7.13E-01 0.25 0.26 3.35E-01 5.20E-01 
GP9 0.15 0.31 6.24E-01 0.44 0.45 3.28E-01 0.24 0.26 3.43E-01 5.20E-01 
GP23 -0.27 0.32 3.94E-01 -0.18 0.47 6.99E-01 -0.24 0.26 3.61E-01 5.30E-01 
GP8 -0.27 0.31 3.88E-01 -0.09 0.47 8.47E-01 -0.21 0.26 4.13E-01 5.81E-01 
GP39 0.12 0.31 6.82E-01 0.39 0.46 3.93E-01 0.21 0.26 4.20E-01 5.81E-01 
GP2 -0.01 0.28 9.72E-01 -0.47 0.43 2.69E-01 -0.14 0.23 5.36E-01 7.20E-01 
GP26 0.18 0.31 5.61E-01 0.09 0.45 8.40E-01 0.15 0.26 5.56E-01 7.27E-01 
GP16 0.08 0.31 8.08E-01 0.19 0.45 6.75E-01 0.11 0.26 6.64E-01 8.44E-01 
GP32 -0.05 0.32 8.83E-01 0.42 0.47 3.64E-01 0.10 0.26 7.04E-01 8.70E-01 
GP35 0.02 0.31 9.38E-01 -0.35 0.46 4.41E-01 -0.09 0.26 7.22E-01 8.70E-01 
GP34 -0.14 0.30 6.39E-01 0.10 0.44 8.20E-01 -0.06 0.25 7.96E-01 8.94E-01 
  
GP1 0.32 0.29 2.75E-01 -0.53 0.45 2.34E-01 0.06 0.25 7.97E-01 8.94E-01 
GP37 -0.19 0.30 5.13E-01 0.23 0.45 6.09E-01 -0.06 0.25 7.99E-01 8.94E-01 
GP13 -0.14 0.30 6.41E-01 0.39 0.46 3.93E-01 0.02 0.25 9.40E-01 9.85E-01 
GP3 -0.11 0.29 6.96E-01 0.21 0.45 6.30E-01 -0.02 0.24 9.47E-01 9.85E-01 
GP17.18 -0.25 0.30 4.09E-01 0.54 0.45 2.30E-01 -0.01 0.25 9.81E-01 9.85E-01 
GP7 0.03 0.31 9.25E-01 -0.05 0.47 9.22E-01 0.01 0.26 9.82E-01 9.85E-01 








Supplemental Figure S1 Marked differences in abundances of individual glycan 
groups (GP30, GP36, GP38) and hsCRP in subjects with young adult-onset non-
autoimmune diabetes, without rare HNF1A alleles and subjects with likely damaging 
HNF1A alleles. Differences in plasma N-glycans and hsCRP are shown as box plots. 
Each box represents the 25th to 75th percentile. Lines inside the boxes represent the 
median. The upper whisker extends from the hinge to the highest value that is within 
1.5 x IQR of the hinge, where IQR is the inter-quartile range, or distance between the 
first and third quartiles. The lower whisker extends from the hinge to the lowest value 
within 1.5 x IQR of the hinge. Circles indicate outliers. GP – glycan peak; CRO – 
Croatian cohort; OX – UK (Oxford) cohort. 
